tnx-103
Generic: levosimendan·Code: TNX-103
tnx-103: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| TENAX THERAPEUTICS, INC. (TENX) | Phase 3 |
Clinical Trials (1)
A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Levosimendan in Pulmonary Hypertension Patients With Heart Failure With Preserved Left Ventricular Ejection Fraction (PH-HFpEF)
Frequently asked questions
Who is developing tnx-103?
tnx-103 is being developed by TENAX THERAPEUTICS, INC..
How many clinical trials involve tnx-103?
BioSniper tracks 1 clinical trial involving tnx-103.
Get deeper analysis on tnx-103
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis